PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 63 | 2 | 203-214
Article title

Halogen bonds involved in binding of halogenated ligands by protein kinases

Content
Title variants
Languages of publication
EN
Abstracts
EN
Analysis of 664 known structures of protein kinase complexes with halogenated ligands revealed 424 short contacts between a halogen atom and a potential protein X-bond acceptor, the topology and geometry of which were analyzed according to the type of a halogen atom (X = Cl, Br, I) and a putative protein X-bond acceptor. Among 236 identified halogen bonds, the most represented ones are directed to backbone carbonyls of the hinge region and may replace the pattern of ATP-like hydrogen bonds. Some halogen-π interactions with either aromatic residues or peptide bonds, that accompany the interaction with the hinge region, may possibly enhance ligand selectivity. Interestingly, many of these halogen-π interactions are bifurcated. Geometrical preferences identify iodine as the strongest X-bond donor, less so bromine, while virtually no such preferences were observed for chlorine; and a backbone carbonyl as the strongest X-bond acceptor. The presence of a halogen atom in a ligand additionally affects the properties of proximal hydrogen bonds, which according to geometrical parameters get strengthened, when a nitrogen of a halogenated ligand acts as the hydrogen bond donor.
Publisher

Year
Volume
63
Issue
2
Pages
203-214
Physical description
Dates
published
2016
received
2015-07-15
revised
2016-02-11
accepted
2016-03-11
(unknown)
2016-04-20
Contributors
  • Institute of Biochemistry and Biophysics PAS, Warszawa, Poland
  • Institute of Biochemistry and Biophysics PAS, Warszawa, Poland
  • Institute of Biochemistry and Biophysics PAS, Warszawa, Poland
  • International Institute of Molecular and Cell Biology, Warszawa, Poland
  • Department - Center of Population Health Monitoring and Analysis, National Institute of Public Health - National Institute of Hygiene, Warszawa, Poland
author
  • Institute of Biochemistry and Biophysics PAS, Warszawa, Poland
References
  • Aakeroey CB, Panikkattu S, Chopade PD, Desper J (2013) Competing hydrogen-bond and halogen-bond donors in crystal engineering. Cryst Eng Comm 15: 3125-3136. doi: 10.1039/C2CE26747K.
  • Anderson TW, Darling DA (1952) Asymptotic theory of certain goodness of fit criteria based on stochastic processes. Ann Math Stat 23: 193-212. doi: 10.1214/aoms/1177729437.
  • Auffinger P, Hays FA, Westhof E, Ho PS (2004) Halogen bonds in biological molecules. Proc Natl Acad Sci USA 101: 16789-16794. doi: 10.1073/pnas.0407607101.
  • Barratt E, Bingham RJ, Warner DJ, Laughton CA, Phillips SE, Homans SW (2005) Van der waals interactions dominate ligand-protein association in a protein binding site occluded from solvent water. J Am Chem Soc 127: 11827-11834. doi: 10.1021/ja0527525.
  • Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA (2001) Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci 10: 2200-2206. doi: 10.1110/ps.19601.
  • Battistutta R, Mazzorana M, Sarno S, Kazimierczuk Z, Zanotti G, Pinna LA (2005) Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. Chem Biol 12: 1211-1219. doi: 10.1016/j.chembiol.2005.08.015.
  • Battistutta R, Mazzorana M, Cendron L, Bortolato A, Sarno S, Kazimierczuk Z, Zanotti G, Moro S, Pinna LA (2007) The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. Chem Bio Chem 8: 1804-1809. doi: 10.1002/cbic.200700307.
  • Battistutta R (2009) Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. Cell Mol Life Sci 66: 1868-1889. doi: 10.1002/9781118482490.ch1.
  • Beale TM, Chudzinski MG, Sarwar MG, Taylor MS (2013) Halogen bonding in solution: thermodynamics and applications. Chem Soc Rev 42: 1667-1680. doi: 10.1039/C2CS35213C.
  • Besant PG, Tan E, Attwood PV (2003) Mammalian protein histidine kinases. Int J Biochem Cell Biol 35: 297-309. doi: 10.1016/S1357-2725(02)00257-1.
  • Besant PG, Attwood PV (2005) Mammalian histidine kinases. Biochim Biophys Acta 1754: 281-290. doi: 10.1016/j.bbapap.2005.07.026.
  • Besant PG, Attwood PV, Piggott MJ (2009) Focus on phosphoarginine and phospholysine. Curr Protein Pept Sci 10: 536-550. doi: 10.2174/138920309789630598.
  • Bogoyevitch MA, Fairlie DP (2007) A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 12: 622-633. doi: 10.1016/j.drudis.2007.06.008.
  • Bondi A (1964) van der Waals volumes and radii. J Phys Chem 68: 441-451. doi: 10.1021/j100785a001.
  • Cabrita MT, Vale C, Rauter AP (2010) Halogenated Compounds from Marine Algae. Mar Drugs 8: 2301-2317. doi: 10.3390/md8082301.
  • Carlsson AC, Veiga AX, Erdélyi M (2015) Halogen bonding in solution. Top Curr Chem 359: 49-76. doi: 10.1039/C2CS15292D.
  • Carter M, Ho PS (2011) Assaying the energies of biological halogen bonds. Cryst Growth Des 11: 5087-5095. doi: 10.1021/cg200991v.
  • Chaikuad A, Tacconi EM, Zimmer J, Liang Y, Gray NS, Tarsounas M, Knapp S (2014) A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol 10: 853-860. doi: 10.1038/nchembio.1629.
  • Ciesla J, Fraczyk T, Rode W (2011) Phosphorylation of basic amino acid residues in proteins: important but easily missed. Acta Biochim Pol 58: 137-147.
  • Clark T, Hennemann M, Murray JS, Politzer P (2007) Halogen bonding: the sigma-hole. J Mol Model 13: 291-296.
  • Cohen P (2002) Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315. doi: 10.1038/nrd773.
  • Couty S, Westwood IM, Kalusa A, Cano C, Travers J, Boxall K, Chow CL, Burns S, Schmitt J, Pickard L, Barillari C, McAndrew PC, Clarke PA, Linardopoulos S, Griffin RJ, Aherne GW, Raynaud FI, Workman P, Jones K, van Montfort RL (2013) The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget 4: 1647-1661. doi: 10.18632/oncotarget.1255.
  • Cowan-Jacob SW, Jahnke W, Knapp S (2014) Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Med Chem 6: 541-561. doi: 10.4155/fmc.13.216.
  • Cozza G, Girardi C, Ranchio A, Lolli G, Sarno S, Orzeszko A, Kazimierczuk Z, Battistutta R, Ruzzene M, Pinna LA (2014) Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cell Mol Life Sci 71: 3173-3185. doi: 10.1007/s00018-013-1552-5.
  • Das K, Clark AD Jr, Lewi PJ, Heeres J, de Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, de Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47: 2550-2560. doi: 10.1021/jm030558s.
  • De Moliner E, Brown NR, Johnson LN (2003) Alternative binding modes of an inhibitor to two different kinases. Eur J Biochem 270: 3174-3181. doi: 10.1046/j.1432-1033.2003.03697.x.
  • DeLano WL, Lam JW (2005) PyMOL: A communications tool for computational models. Abstr Pap Am Chem Soc 230: U1371-U1372. doi: 10.1371/journal.pone.0027543.
  • Desiraju GR, Ho PS, Kloo L, Legon AC, Marquardt R, Metrangolo P, Politzer P, Resnati G, Rissanen K (2013) Definition of the halogen bond (IUPAC Recommendations 2013). Pure Appl Chem 85: 1711-1713. doi: 10.1351/PAC-REC-12-05-10.
  • Dietrich J, Hulme C, Hurley LH (2010) The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec (R), Nexavar (R), and BIRB-796. Bioorg Med Chem 18: 5738-5748. doi: 10.1016/j.bmc.2010.05.063.
  • Dunitz JD (2004) Organic fluorine: Odd man out. Chem Bio Chem 5: 614-621. doi: 10.1002/cbic.200300801.
  • Eckenhoff RG, Johansson JS (1997) Molecular interactions between inhaled anesthetics and proteins. Pharmacol Rev 49: 343-367.
  • Elsholz AK, Turgay K, Michalik S, Hessling B, Gronau K, Oertel D, Mader U, Bernhardt J, Becher D, Hecker M, Gerth U (2012) Global impact of protein arginine phosphorylation on the physiology of Bacillus subtilis. Proc Natl Acad Sci USA 109: 7451-7456. doi: 10.1073/pnas.1117483109.
  • Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. doi: 10.1107/S0907444904019158.
  • Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501. doi: 10.1107/S0907444910007493.
  • Fabbro D (2015) 25 Years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol 87: 766-775. doi: 10.1124/mol.114.095489.
  • Feng J, Zhu M, Schaub MC, Gehrig P, Roschitzki B, Lucchinetti E, Zaugg M (2008) Phosphoproteome analysis of isoflurane-protected heart mitochondria: phosphorylation of adenine nucleotide translocator-1 on Tyr(194) regulates mitochondrial function. Cardiovasc Res 80: 20-29. doi: 10.1093/cvr/cvn161.
  • Fischer PM (2004) The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr Med Chem 11: 1563-1583. doi: 10.2174/0929867043365062.
  • Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, Carr D, Zhu H, Wong J, Yang RS, Le HV, Madison VS (2009) Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 48: 2661-2674. doi: 10.1021/bi801898e.
  • Fuhrmann J, Schmidt A, Spiess S, Lehner A, Turgay K, Mechtler K, Charpentier E, Clausen T (2009) McsB Is a protein arginine kinase that phosphorylates and inhibits the heat-shock regulator CtsR. Science 324: 1323-1327. doi: 10.1126/science.1170088.
  • Garuti L, Roberti M, Bottegoni G (2010) Non-ATP competitive protein kinase inhibitors. Curr Med Chem 17: 2804-2821. doi: 10.2174/092986710791859333.
  • Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J, Farrell R, Frauchiger S, La Fargue J, Ghate M, Graves B, Hill RJ, Li FJ, Litman R, Loe B, McIntosh J, McWeeney D, Papp E, Park J, Reese HF, Roberts RT, Rotstein D, Pablo BS, Sarma K, Stahl M, Sung ML, Suttman RT, Sjogren EB, Tan YC, Trejo A, Welch M, Weller P, Wong BR, Zecic H (2011) Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38 alpha mitogen-activated protein kinase. J Med Chem 54: 2255-2265.
  • Gower CM, Chang ME, Maly DJ (2014) Bivalent inhibitors of protein kinases. Crit Rev Biochem Mol Biol 49: 102-115. doi: 10.3109/10409238.2013.875513.
  • Hardegger LA, Kuhn B, Spinnler B, Anselm L, Ecabert R, Stihle M, Gsell B, Thoma R, Diez J, Benz J, Plancher JM, Hartmann G, Banner DW, Haap W, Diederich F (2011) Systematic investigation of halogen bonding in protein-ligand interactions. Angew Chem Int Ed Engl 50: 314-318. doi: 10.1002/anie.201006781.
  • Harrison S, Das K, Karim F, Maclean D, Mendel D (2008) Non-ATP-competitive kinase inhibitors - enhancing selectivity through new inhibition strategies. Expert Opin Drug Discov 3: 761-774. doi: 10.1517/17460441.3.7.761.
  • Hauchecorne D, van der Veken BJ, Moiana A, Herrebout WA (2010) The C-Cl∙∙∙N halogen bond, the weaker relative of the C∙∙∙I and C-Br∙∙∙N halogen bonds, finally characterized in solution. Chem Phys 374: 30-36. doi: 10.1016/j.chemphys.2010.06.004.
  • Hendsch ZS, Tidor B (1994) Do salt bridges stabilize proteins? A continuum electrostatic analysis. Protein Sci 3: 211-226. doi: 10.1002%2Fpro.5560030206.
  • Hernandes MZ, Cavalcanti SM, Moreira DR, de Azevedo Junior WF, Leite AC (2010) Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets 11: 303-314. doi: 10.2174/138945010790711996.
  • Howard JAK, Hoy VJ, OHagan D, Smith, GT (1996) How good is fluorine as a hydrogen bond acceptor? Tetrahedron 52: 12613-12622. doi: 10.1016/0040-4020(96)00749-1.
  • Hubig SM, Lindeman SV, Kochi JK (2000) Charge-transfer bonding in metal-arene coordination. Coord Chem Rev 200: 831-873. doi: 10.1016/S0010-8545(00)00322-2.
  • Ibrahim MA (2011) Molecular mechanical study of halogen bonding in drug discovery. J Comput Chem 32: 2564-2574. doi: 10.1002/jcc.21836.
  • Ibrahim MA (2012) AMBER empirical potential describes the geometry and energy of noncovalent halogen interactions better than advanced semiempirical quantum mechanical method PM6-DH2X. J Phys Chem B 116: 3659-3669. doi: 10.1021/jp3003905.
  • Joosten RP, Long F, Murshudov GN, Perrakis A (2014) The PDB_REDO server for macromolecular structure model optimization. IUCrJ 1: 213-220. doi: 10.1107/S2052252514009324.
  • Jorgensen WL, Schyman P (2012) Treatment of halogen bonding in the OPLS-AA force field: application to potent anti-HIV agents. J Chem Theory Comput 8: 3895-3901. doi: 10.1021/ct300180w.
  • Khorasanizadeh S (2004) The nucleosome: From genomic organization to genomic regulation. Cell 116: 259-272. doi: 10.1016/S0092-8674(04)00044-3.
  • Kirkland LO, McInnes C (2009) Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol 77: 1561-1571. doi: 10.1016/j.bcp.2008.12.022.
  • Kleywegt GJ, Harris MR, Zou JY, Taylor TC, Wahlby A, Jones TA (2004) The Uppsala Electron-Density Server. Acta Crystallogr D Biol Crystallogr 60: 2240-2249. doi: 10.1107/S0907444904013253.
  • Klumpp S, Krieglstein J (2002) Phosphorylation and dephosphorylation of histidine residues in proteins. Eur J Biochem 269: 1067-1071. doi: 10.1046/j.1432-1033.2002.02755.x.
  • Kolar M, Hobza P (2012) On extension of the current biomolecular empirical force field for the description of halogen bonds. J Chem Theory Comput 8: 1325-1333. doi: 10.1021/ct2008389.
  • Koshland DE (1994) The key-lock theory and the induced fit theory. Angew Chem Int Ed 33: 2375-2378. doi: 10.1002/anie.199423751.
  • Kraut DA, Churchill MJ, Dawson PE, Herschlag D (2009) Evaluating the potential for halogen bonding in the oxyanion hole of ketosteroid isomerase using unnatural amino acid mutagenesis. ACS Chem Biol 4: 269-273. doi: 10.1021/cb900016q.
  • Krieger E, Joo K, Lee J, Lee J, Raman S, Thompson J, Tyka M, Baker D, Karplus K (2009) Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins 77: 114-122. doi: 10.1002%2Fprot.22570.
  • Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Amer Statist Assoc 47: 583-621.
  • Kuglstatter A, Wong A, Tsing S, Lee SW, Lou Y, Villaseñor AG, Bradshaw JM, Shaw D, Barnett JW, Browner MF (2011) Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Sci 20: 428-436. doi: 10.100/2Fpro.575.
  • Lamba V, Ghosh I (2012) New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Curr Pharm Des 18: 2936-2945. doi: 10.2174/138161212800672813.
  • Lapek JD Jr, Tombline G, Kellersberger KA, Friedman MR, Friedman AE (2015) Evidence of histidine and aspartic acid phosphorylation in human prostate cancer cells. Naunyn Schmiedebergs Arch Pharmacol 388: 161-173. doi: 10.1007/s00210-014-1063-4.
  • Lepsik M, Rezac J, Kolar M, Pecina A, Hobza P, Fanfrlik J (2013) The semiempirical quantum mechanical scoring function for in silico drug design. Chem Plus Chem 78: 921-931. doi: 10.1002/cplu.201300199.
  • Li H, Lu Y, Liu Y, Zhu X, Liu H, Zhu W (2012) Interplay between halogen bonds and pi-pi stacking interactions: CSD search and theoretical study. Phys Chem Chem Phys 14: 9948-9955. doi: 10.1039/c2cp41149k.
  • Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 20: 146-159. doi: 10.1016/j.chembiol.2012.12.006.
  • Liu RY, Loll PJ, Eckenhoff RG (2005) Structural basis for high-affinity volatile anesthetic binding in a natural 4-helix bundle protein. FASEB J 19: 567-576. doi: 10.1096/fj.04-3171com.
  • Lu Y-X, Zou J-W, Wang Y-H, Yu Q-S (2006) Bifurcated halogen bonds: An ab initio study of the three-center interactions. J Mol Struct Theochem 767: 139-142. doi: 10.1016/j.theochem.2006.05.024.
  • Lu YX, Shi T, Wang Y, Yang HY, Yan XH, Luo XM, Jiang HL, Zhu WL (2009) Halogen bonding--a novel interaction for rational drug design? J Med Chem 52: 2854-2862. doi: 10.1021/jm9000133.
  • Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18: 50-60. doi: 10.1214/aoms/1177730491.
  • Massey FJ (1951) The distribution of the maximum deviation between 2 sample cumulative step functions. Ann Math Stat 22: 125-128.
  • Matthews HR (1995) Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins - a possible regulator of the mitogen-activated protein-kinase cascade. Pharmacol Ther 67: 323-350. doi: 10.1016/0163-7258(95)00020-8.
  • Memic A, Spaller MR (2008) How do halogen substituents contribute to protein-binding interactions? A thermodynamic study of peptide ligands with diverse aryl halides. Chem Bio Chem 9: 2793-2795. doi: 10.1002/cbic.200800572.
  • Metrangolo P, Neukirch H, Pilati T, Resnati G (2005) Halogen bonding based recognition processes: A world parallel to hydrogen bonding. Acc Chem Res 38: 386-395. doi: 10.1021/ar0400995.
  • Metrangolo P, Meyer F, Pilati T, Resnati G, Terraneo G (2008) Halogen bonding in supramolecular chemistry. Angew Chem Int Ed Engl 47: 6114-6127. doi: 10.1021/cr500674c.
  • Nazare M, Will DW, Matter H, Schreuder H, Ritter K, Urmann M, Essrich M, Bauer A, Wagner M, Czech J, Lorenz M, Laux V, Wehner V (2005) Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: A study combining structure-activity relationship and X-ray crystallography. J Med Chem 48: 4511-4525. doi: 10.1021/jm0490540.
  • Niefind K, Raaf J, Issinger OG (2009) Protein kinase CK2 in health and disease: Protein kinase CK2: From structures to insights. Cell Mol Life Sci 66: 1800-1816. doi: 10.1007/s00018-009-9149-8.
  • Novak M, Foroutan-Nejad C, Marek R (2015) Asymmetric bifurcated halogen bonds. Phys Chem Chem Phys 17: 6440-6450. doi: 10.1039/C4CP05532B.
  • Pannifer AD, Flint AJ, Tonks NK, Barford D (1998) Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by X-ray crystallography. J Biol Chem 273: 10454-10462. doi: 10.1074/jbc.273.17.10454.
  • Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, Cole PA (2001) Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 8: 37-41. doi: 10.1038/83028.
  • Parang K, Cole PA (2002) Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther 93: 145-157. doi: 10.1016/S0163-7258(02)00184-5.
  • Parisini E, Metrangolo P, Pilati T, Resnati G, Terraneo G (2011) Halogen bonding in halocarbon-protein complexes: a structural survey. Chem Soc Rev 40: 2267-2278. doi: 10.1039/c0cs00177e.
  • Pauletti PM, Cintra LS, Braguine CG, da Silva Filho AA, Silva ML, Cunha WR, Januario AH (2010) Halogenated indole alkaloids from marine invertebrates. Mar Drugs 8: 1526-1549. doi: 10.3390/md8051526.
  • Persch E, Dumele O, Diederich F (2015) Molecular recognition in chemical and biological systems. Angew Chem Int Ed Engl 54: 3290-3327. doi: 10.1002/anie.201408487.
  • Pflug A, Johnson KA, Engh RA (2012) Anomalous dispersion analysis of inhibitor flexibility: a case study of the kinase inhibitor H-89. Acta Crystallogr Sect F Struct Biol Cryst Commun 68: 873-877. doi: 10.1107/S1744309112028655.
  • Politzer P, Murray JS, Concha MC (2007) Halogen bonding and the design of new materials: organic bromides, chlorides and perhaps even fluorides as donors. J Mol Model 13: 643-650. doi: 10.1007/s00894-007-0176-9.
  • Poznanski J, Najda A, Bretner M, Shugar D (2007) Experimental (13C NMR) and theoretical (ab initio molecular orbital calculations) studies on the prototropic tautomerism of benzotriazole and some derivatives symmetrically substituted on the benzene ring. J Phys Chem A 111: 6501-6509. doi: 10.1021/jp071611h.
  • Poznanski J, Shugar D (2013) Halogen bonding at the ATP binding site of protein kinases: Preferred geometry and topology of ligand binding. Biochim Biophys Acta 1834: 1381-1386. doi: 10.1016/j.bbapap.2013.01.026.
  • Poznanski J, Poznanska A, Shugar D (2014) A protein data bank survey reveals shortening of intermolecular hydrogen bonds in ligand-protein complexes when a halogenated ligand is an H-bond donor. PLoS One 9: e99984. doi: 10.1371/journal.pone.0099984.
  • Reddy DS, Craig DC, Desiraju GR (1996) Supramolecular synthons in crystal engineering. 4. Structure simplification and synthon interchangeability in some organic diamondoid solids. J Am Chem Soc 118: 4090-4093. doi: 10.1021/ja953373m.
  • Rendine S, Pieraccini S, Forni A, Sironi M (2011) Halogen bonding in ligand-receptor systems in the framework of classical force fields. Phys Chem Chem Phys 13: 19508-19516. doi: 10.1039/c1cp22436k.
  • Richardson CM, Williamson DS, Parratt MJ, Borgognoni J, Cansfield AD, Dokurno P, Francis GL, Howes R, Moore JD, Murray JB, Robertson A, Surgenor AE, Torrance CJ (2006) Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett 16: 1353-1357. doi: 10.1016/j.bmcl.2005.11.048.
  • Robarge KD, Lee W, Eigenbrot C, Ultsch M, Wiesmann C, Heald R, Price S, Hewitt J, Jackson P, Savy P, Burton B, Choo EF, Pang J, Boggs J, Yang A, Yang X, Baumgardner M (2014) Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479. Bioorg Med Chem Lett 24: 4714-4723. doi: 10.1016/j.bmcl.2014.08.008.
  • Rosokha SV, Kochi JK (2008) X-ray structures and electronic spectra of the pi-halogen complexes between halogen donors and acceptors with pi-receptors. Halogen Bonding: Fundamentals and Applications 126: 137-160.
  • Sarno S, Papinutto E, Franchin C, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Orzeszko A, Zanotti G, Battistutta R, Pinna LA (2011) ATP site-directed inhibitors of protein kinase ck2: an update. Curr Top Med Chem 11: 1340-1351. doi: 10.2174/156802611795589638.
  • Sarwar MG, Dragisic B, Salsberg LJ, Gouliaras C, Taylor MS (2010) Thermodynamics of halogen bonding in solution: substituent, structural, and solvent effects. J Am Chem Soc 132: 1646-1653. doi: 10.1021/ja9086352.
  • Scholfield MR, Zanden CM, Carter M, Ho PS (2013) Halogen bonding (X-bonding): A biological perspective. Protein Sci 22: 139-152. doi: 10.1002/pro.2201.
  • Schulze-Gahmen U, De Bondt HL, Kim SH (1996) High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: Bound waters and natural ligand as guides for inhibitor design. J Med Chem 39: 4540-4546. 10.1021/jm960402a.
  • Smit AJ (2004) Medicinal and pharmaceutical uses of seaweed natural products: A review. J Appl Phycol 16: 245-262. doi: 10.1023/B:JAPH.0000047783.36600.ef.
  • Steeg PS, Palmieri D, Ouatas T, Salerno M (2003) Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer. Cancer Lett 190: 1-12 doi: 10.1016/S0304-3835(02)00499-8.
  • Steinig AG, Li AH, Wang J, Chen X, Dong H, Ferraro C, Jin M, Kadalbajoo M, Kleinberg A, Stolz KM, Tavares-Greco PA, Wang T, Albertella MR, Peng Y, Crew L, Kahler J, Kan J, Schulz R, Cooke A, Bittner M, Turton RW, Franklin M, Gokhale P, Landfair D, Mantis C, Workman J, Wild R, Pachter J, Epstein D, Mulvihill MJ (2013) Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. Bioorg Med Chem Lett 23: 4381-4387. doi: 10.1016/j.bmcl.2013.05.074 .
  • Tong YS, Lin NH, Wang L, Hasvold L, Wang WB, Leonard N, Li TM, Li Q, Cohen J, Gu WZ, Zhang HY, Stoll V, Bauch J, Marsh K, Rosenberg SH, Sham HL (2003) Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability. Bioorg Med Chem Lett 13: 1571-1574. doi: 10.1016/S0960-894X(03)00195-1.
  • Ventimig FA, Wool IG (1974) A kinase that transfers the gamma-phosphoryl group of GTP to proteins of eukaryotic 40s ribosomal-subunits. Proc Natl Acad Sci USA 71: 350-354.
  • Voth AR, Hays FA, Ho PS (2007) Directing macromolecular conformation through halogen bonds. Proc Natl Acad Sci USA 104: 6188-6193. doi: 10.1073/pnas.0610531104.
  • Voth AR, Ho PS (2007) The role of halogen bonding in inhibitor recognition and binding by protein kinases. Curr Top Med Chem 7: 1336-1348. doi: 10.2174/156802607781696846.
  • Voth AR, Khuu P, Oishi K, Ho PS (2009) Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 1: 74-79. doi: 10.1038/nchem.112.
  • Wagner PD, Vu ND (2000) Histidine to aspartate phosphotransferase activity of nm23 proteins: phosphorylation of aldolase C on Asp-319. Biochem J 346: 623-630. doi: 10.1042/0264-6021:3460623.
  • Wang L, Gao J, Bi F, Song B, Liu C (2014) Toward the development of the potential with angular distortion for halogen bond: a comparison of potential energy surfaces between halogen bond and hydrogen bond. J Phys Chem A 118: 9140-9147. doi: 10.1021/jp502739c.
  • Wang W, Okada Y, Shi HB, Wang YQ, Okuyama T (2005) Structures and aldose reductase inhibitory effects of bromophenols from the red alga Symphyocladia latiuscula. J Nat Prod 68: 620-622. doi: 10.1021/np040199j.
  • Wasik R, Lebska M, Felczak K, Poznanski J, Shugar D (2010) Relative role of halogen bonds and hydrophobic interactions in inhibition of human protein kinase CK2 alpha by tetrabromobenzotriazole and some c(5)-substituted analogues. J Phys Chem B 114: 10601-10611. doi: 10.1021/jp102848y.
  • Wasik R, Winska P, Poznanski J, Shugar D (2012a) Synthesis and physico-chemical properties in aqueous medium of all possible isomeric bromo analogues of benzo-1H-triazole, potential inhibitors of protein kinases. J Phys Chem B 116: 7259-7268. doi: 10.1021/jp301561x.
  • Wasik R, Winska P, Poznanski J, Shugar D (2012b) Isomeric mono-, di-, and tri-bromobenzo-1H-triazoles as inhibitors of human protein kinase CK2α. PLoS One 7: e48898. doi: 10.1371/journal.pone.0048898.
  • Wenglowsky S, Ren L, Ahrendt KA, Laird ER, Aliagas I, Alicke B, Buckmelter AJ, Choo EF, Dinkel V, Feng B, Gloor SL, Gould SE, Gross S, Gunzner-Toste J, Hansen JD, Hatzivassiliou G, Liu B, Malesky K, Mathieu S, Newhouse B, Raddatz NJ, Ran Y, Rana S, Randolph N, Risom T, Rudolph J, Savage S, Selby LT, Shrag M, Song K, Sturgis HL, Voegtli WC, Wen Z, Willis BS, Woessner RD, Wu WI, Young WB, Grina J (2011) Pyrazolopyridine inhibitors of B-Raf(V600E). Part 1: the development of selective, orally bioavailable, and efficacious inhibitors. ACS Med Chem Lett 2: 342-347. doi: 10.1021/ml200025q.
  • Wilcken R, Zimmermann MO, Lange A, Joerger AC, Boeckler FM (2013) Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem 56: 1363-1388. doi: 10.1021/jm3012068.
  • Winiewska M, Kucińska K, Makowska M, Poznański J, Shugar D (2015a) Thermodynamics parameters for binding of halogenated benzotriazole inhibitors of human protein kinase CK2α. Biochim Biophys Acta 1854: 1708-1717. doi: 10.1016/j.bbapap.2015.04.004.
  • Winiewska M, Makowska M, Maj P, Wielechowska M, Bretner M, Poznanski J, Shugar D (2015b) Thermodynamic parameters for binding of some halogenated inhibitors of human protein kinase CK2. Biochem Biophys Res Commun 456: 282-287. doi: 10.1016/j.bbrc.2014.11.072.
  • Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB (2013) Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5: 216ra177. doi: 10.1126/scitranslmed.3007205.
  • Zhang JM, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39. doi: 10.1038/nrc2559.
  • Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu QS, Gray NS (2014) Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol 9: 1230-1241. doi: 10.1021/cb500129t.
  • Zien P, Bretner M, Zastapilo K, Szyszka R, Shugar D (2003) Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. Biochem Biophys Res Commun 306: 129-133. doi: 10.1016/S0006-291X(03)00928-8.
  • Zou WS, Han J, Jin WJ (2009) Concentration-dependent Br∙∙∙O halogen bonding between carbon tetrabromide and oxygen-containing organic solvents. J Phys Chem A 113: 10125-10132. doi: 10.1021/jp905914q.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv63p203kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.